MSRA is non differenciated in this study, pretty easy to understand given the sample size. MSRA is generally contracted in a hospital setting where drug resistance is prevalent, not in the general population which would constitute this study cohort. It is certainly upto BOT to demonstrate MSRA elimination in future studies but this was not it, nor was it an end point.
Permetrix key to inflamatory? Highly likely acne is effective due to antibacterial and not as effective where hormonal drivers are an issue. You will need to wait for phase 3 results to have a tanty about that but you dont hold so why care?
Ann: Phase 2a Study Shows BTX 1801 Eradicates S. Aureus, page-579
-
- There are more pages in this discussion • 422 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
0.015(4.76%) |
Mkt cap ! $597.3M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.5¢ | 32.3¢ | $1.265M | 3.862M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 129446 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 131308 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |